E. Breitbart

发表

Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I.

Y. Shoenfeld, B. Gilburd, D. Harats, 2004, Cardiovascular research.

Systemic Administration of a Conditionally Replicating Adenovirus, Targeted to Angiogenesis, Reduced Lung Metastases Burden in Cotton Rats

I. Barshack, D. Harats, S. Greenberger, 2009, Clinical Cancer Research.

Transcription-controlled gene therapy against tumor angiogenesis.

I. Barshack, D. Harats, D. Wallach, 2004, The Journal of clinical investigation.

Vascular Wall Maturation and Prolonged Angiogenic Effect by Endothelial-Specific Platelet-Derived Growth Factor Expression

I. Barshack, D. Harats, S. Greenberger, 2006, Pathobiology.

Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK

I. Barshack, D. Harats, D. Ben-Shushan, 2009, Cancer biology & therapy.

Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors

A. Brenner, E. Borden, D. Harats, 2013, Clinical Cancer Research.

VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme

A. Brenner, Jessica R. Miller, D. Cavazos, 2015, Journal of Neuro-Oncology.

Abstract 3283: VB-111 a novel anti-angiogenic vector and a promising treatment for metastatic cancer in combination with other anticancer drugs

Y. Cohen, E. Breitbart, L. Bangio, 2011 .

Endothelial-targeted Gene Transfer of Hypoxia-inducible Factor-1α Augments Ischemic Neovascularization Following Systemic Administration.

I. Barshack, D. Harats, E. Feige, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Activation of C-transactivation domain is essential for optimal HIF-1 alpha-mediated transcriptional and angiogenic effects.

D. Harats, A. Shaish, R. Tal, 2008, Microvascular research.

A Lecinoxoid, an oxidized phospholipid small molecule, constrains CNS autoimmune disease

E. Feige, I. Mendel, E. Breitbart, 2010, Journal of Neuroimmunology.

Treatment with lecinoxoids attenuates focal and segmental glomerulosclerosis development in nephrectomized rats

A. Volkov, B. Feldman, I. Mendel, 2018, Basic & clinical pharmacology & toxicology.

Identification of Motile Sperm Domain–Containing Protein 2 as Regulator of Human Monocyte Migration

I. Mendel, N. Yacov, E. Breitbart, 2017, The Journal of Immunology.

Inhibition of monocyte chemotaxis by VB-201, a small molecule lecinoxoid, hinders atherosclerosis development in ApoE⁻/⁻ mice.

J. George, D. Harats, E. Feige, 2013, Atherosclerosis.

Aging and the human immune system.

B. Stollar, E. Breitbart, 2000, The Israel Medical Association journal : IMAJ.

Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect

I. Barshack, D. Harats, D. Ben-Shushan, 2008, Cancer Gene Therapy.

Newly characterized motile sperm domain‐containing protein 2 promotes human breast cancer metastasis

I. Mendel, N. Yacov, E. Breitbart, 2018, International journal of cancer.

Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models.

N. Eberhardt, D. Harats, H. Reddi, 2011, Genes & cancer.

Altered memory B-cell homeostasis in human aging.

Xiaowei Wang, S. Meydani, G. Dallal, 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

MOSPD2 is a therapeutic target for the treatment of CNS inflammation

B. Feldman, I. Mendel, N. Yacov, 2020, Clinical and experimental immunology.

Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis

I. Mendel, N. Yacov, E. Breitbart, 2016, Digestive Diseases and Sciences.

VB‐201, an oxidized phospholipid small molecule, inhibits CD14‐ and Toll‐like receptor‐2‐dependent innate cell activation and constrains atherosclerosis

J. George, D. Harats, E. Feige, 2014, Clinical and experimental immunology.

Specific Induction of Tumor Neovasculature Death by Modified Murine PPE-1 Promoter Armed with HSV-TK

I. Barshack, D. Harats, S. Greenberger, 2008, Pathobiology.

Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.

P. Wen, L. Freedman, A. Brenner, 2016 .

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study

P. Wen, T. Cloughesy, L. Freedman, 2019, Neuro-oncology.

Abstract 4979: Ofranergene Obadenovec (VB-111), an anti-cancer gene therapy, induces immunologic responses in solid tumors transforming cold tumors to hot tumors

I. Barshack, D. Harats, R. Shapira-Frommer, 2019, Immunology.

VB‐201, an oxidized phospholipid small molecule, inhibits CD14‐ and Toll‐like receptor‐2‐dependent innate cell activation and constrains atherosclerosis

D. Harats, I. Mendel, N. Yacov, 2014, Clinical and experimental immunology.

Abstract 5400: Antiangiogenic gene therapy with VB111 is active in glioblastoma xenografts

Andrew Brenner, A. Brenner, Y. Cohen, 2011 .